Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $300 | $302 | $279 | $266 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Cost of Goods Sold | $129 | $123 | $113 | $110 |
| Gross Profit | $171 | $179 | $166 | $157 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| R&D Expenses | $24 | $25 | $28 | $26 |
| G&A Expenses | $88 | $92 | $96 | $84 |
| SG&A Expenses | $88 | $92 | $96 | $84 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $12 | $23 | $45 | $10 |
| Operating Expenses | $124 | $140 | $169 | $121 |
| Operating Income | $47 | $39 | -$3 | $36 |
| % Margin | 15.6% | 12.8% | -1.1% | 13.5% |
| Other Income/Exp. Net | $1 | -$9 | -$3 | -$0 |
| Pre-Tax Income | $47 | $30 | -$6 | $36 |
| Tax Expense | $12 | $3 | $9 | $8 |
| Net Income | $36 | $27 | -$15 | $27 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS | 103.98 | 72.59 | -38.58 | 68.07 |
| % Growth | 43.2% | 288.2% | -156.7% | – |
| EPS Diluted | 103.68 | 72.37 | -38.58 | 67.97 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $2 | $1 | $3 |
| Interest Expense | $3 | $3 | $1 | $1 |
| Depreciation & Amortization | $9 | $18 | $17 | $17 |
| EBITDA | $59 | $51 | $13 | $53 |
| % Margin | 19.7% | 16.8% | 4.6% | 19.9% |